Project Grant R43AI102294

Federal Project Grant Award Summary Orpro Therapeutics Inc. received a $508,988 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 24, 2025, with completion targeted for August 31, 2026. The award funds the development and evaluation of ORP100S, an engineered monothiol variant of human thioredoxin-1 (TRX), designed to mitigate radiation-induced lung injury...

Project Grant Award Summary Antigen Discovery Inc. (also operating as Immport Therapeutics Inc.) received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of August 25, 2025, and completion date of July 31, 2027. The project deliverables focus on developing a sensitive and specific serological potency test (PSPT) for whole cell pertussis vaccines to...

Federal Project Grant Award Summary Via Therapeutics, LLC received a $314,363 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 18, 2025 through August 31, 2026. The company will develop an inhaled, fixed-dose combination (I-FDC) powder product containing both azithromycin and amikacin utilizing its proprietary thin-film freeze-drying technology. This combination...

Federal Project Grant Summary Solaris Vaccines, Inc. received a $269,874 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025 through July 31, 2027. The award funds development and evaluation of SOLAVAX-TB, a whole-cell inactivated Mycobacterium tuberculosis vaccine designed to address critical gaps in existing tuberculosis prevention. The vaccine uses a novel...

Shy Therapeutics, LLC received a $300,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 1, 2025, through August 31, 2027. The award supports the development of a novel class of antifungal small-molecule therapeutics designed to address the growing public health threat of drug-resistant fungal infections. The project will deliver research products including...

Microbiotix, Inc. received a $1,023,646 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to develop oxadiazole inhibitors targeting bacterial nonstop ribosome rescue mechanisms. The award, effective August 1, 2025 through July 31, 2027, supports research and development of novel pharmaceutical compounds designed to treat tick-borne diseases, specifically Lyme disease and tularemia in military personnel, veterans, and...

Federal Grant Award Summary Mesa Science Associates, Inc. received a $980,358 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 25, 2025, with completion targeted for August 31, 2028. The award funds the completion of pre-Investigational New Drug (IND) studies for cobinamide, an advanced cyanide antidote formulation developed as bis(aminotetrazolyl)cobinamide. This research...

Federal Grant Award Summary Biotherapeutics, Inc. received a $314,363 Project Grant award on August 13, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). This Small Business Innovation Research (SBIR) Phase 1 grant supports the development of a novel, host-targeted, antibiotic-sparing oral therapeutic designed to treat the concomitant occurrence of Clostridioides difficile infection (CDI) and...

Federal Grant Award Summary: DOXY4STICARE The National Institute of Allergy and Infectious Diseases (NIAID) awarded $837,463 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 4, 2025, to conduct a comprehensive research study examining doxycycline post-exposure prophylaxis (DOXY-PEP) for sexually transmitted infections (STIs). The five-year project, concluding July 31, 2030,...

Federal Grant Award Summary The University of Pittsburgh received a $547,988 Project Grant award dated August 11, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research and development of a novel monkeypox virus (MPXV) vaccine delivery system through September 2024. The project focuses on testing a replication-inducible ACAM2000 vaccine variant engineered through genetic...